" class="no-js "lang="en-US"> Pneumagen - Medtech Alert
Saturday, March 14, 2026

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Pneumagen | Pharmtech Focus

Pneumagen

About Pneumagen

Pneumagen

PNEUMAGEN LIMITED is a biotechnology company based out of St. Andrews, Scotland

Related Story

COVID-19

 Pneumagen Further Strengthens IP Protection for Lead Product Neumifil with Granting of US Composition of Matter Patent | MTA

Pneumagen Further Strengthens IP Protection for Lead Product Neumifil with Granting of US Composition of Matter Patent

April 19 2023

Pneumagen, a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis […]

Diseases

Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

January 19 2022

Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis […]